LENZ Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.966

+110%

-0.917

+72.96%

-0.783

+47.8%

Estimates Revision

The market is revising Upward the revenue expectations for LENZ Therapeutics, Inc. (LENZ) for FY2025, with the revenue forecasts being adjusted by 37.21% over the past three months. During the same period, the stock price has changed by -61.67%.

Revenue Estimates for FY2025

Revise Upward

+37.21%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.39%

In Past 3 Month

Stock Price

Go Down

-61.67%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast LENZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LENZ is 56.60 USD with a low forecast of 52.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

52.00

Averages

56.60

High

62.00

Current: 0.000

Low

52.00

Averages

56.60

High

62.00

H.C. Wainwright

Buy

maintain

$56

2025-12-15

Reason

H.C. Wainwright

Price Target

$56

2025-12-15

maintain

Buy

Reason

H.C. Wainwright attributes the selloff in Lenz Therapeutics shares on Friday to an identified retinal tear for a Vizz presbyopia eye drop patient listed in the FDA's Adverse Event Reporting System public database. The firm views the selloff as an overreaction, saying the patient did not receive a recent standard peripheral retinal examination before initiating Vizz therapy, which contradicts FDA labeled advisement for retinal examination in all patients prior to initiation of therapy. In addition, the patient had an established history of retinal disease, the analyst tells investors in a research note. H.C. Wainwright reiterates a Buy rating on the shares with a $56 price target.

BofA

Jason Gerberry

Buy

maintain

$44 -> $53

2025-08-03

Reason

BofA

Jason Gerberry

Price Target

$44 -> $53

2025-08-03

maintain

Buy

Reason

BofA analyst Jason Gerberry raised the firm's price target on Lenz Therapeutics to $53 from $44 and keeps a Buy rating on the shares. The firm cites the company's Vizz FDA approval and Q2 report the target increase. It believes Lenz's peak sales opportunity for Vizz is being underappreciated at current share levels.

Citi

Buy

maintain

$49 -> $52

2025-08-01

Reason

Citi

Price Target

$49 -> $52

2025-08-01

maintain

Buy

Reason

Citi raised the firm's price target on Lenz Therapeutics to $52 from $49 and keeps a Buy rating on the shares after the FDA approved Vizz a week earlier than the action date. The firm says Lenz has a week "head-start" to start commercialization of the drug.

H.C. Wainwright

NULL -> Buy

upgrade

$38 -> $48

2025-07-28

Reason

H.C. Wainwright

Price Target

$38 -> $48

2025-07-28

upgrade

NULL -> Buy

Reason

H.C. Wainwright raised the firm's price target on Lenz Therapeutics to $48 from $38 and keeps a Buy rating on the shares. The firm sees positive key opinion leader sentiment for LNZ100, a daily eye drop for presbyopia, heading into the August 8 FDA action date.

HC Wainwright & Co.

Matthew Caufield

Strong Buy

Reiterates

$30

2025-04-16

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

$30

2025-04-16

Reiterates

Strong Buy

Reason

Piper Sandler

Biren Amin

Buy

Maintains

$38 → $51

2025-04-14

Reason

Piper Sandler

Biren Amin

Price Target

$38 → $51

2025-04-14

Maintains

Buy

Reason

Piper Sandler analyst Biren Amin assumed coverage of Lenz Therapeutics (LENZ) with an Overweight rating with a price target of $51, up from $38, on the potential of LNZ100, an acelidine-based topical eyedrop for presbyopia, which affects about 128M individuals in the U.S. With the NDA accepted last October and a PDUFA assigned for August 8, 2025, LNZ100 is on track to launch in Q4 2025. The firm believes LNZ100 has a best-in-indication profile, superior to AbbVie's (ABBV) Vuity and Tenpoint's Bramichol. Piper's model estimates U.S. sales of $58M in 2026, growing to $592M by 2035.

Valuation Metrics

The current forward P/E ratio for LENZ Therapeutics Inc (LENZ.O) is -4.94, compared to its 5-year average forward P/E of -10.35. For a more detailed relative valuation and DCF analysis to assess LENZ Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-10.35

Current PE

-4.94

Overvalued PE

-7.96

Undervalued PE

-12.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-8.37

Current EV/EBITDA

-3.87

Overvalued EV/EBITDA

-5.37

Undervalued EV/EBITDA

-11.37

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

49.69

Current PS

17.88

Overvalued PS

95.92

Undervalued PS

3.47

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

LENZ News & Events

Events Timeline

No data

News

7.0

01-08PRnewswire

LENZ Therapeutics Faces Investigation After VIZZ Eye Drop Incident, Stock Plummets 26%

5.0

01-08NASDAQ.COM

LENZ Secures FDA Approval for VIZZ Eye Drops, Reports $1.6M Q4 Revenue

5.0

01-07Globenewswire

LENZ Launches VIZZ Eye Drops, Achieves $1.6 Million in First Quarter Revenue

People Also Watch

Frequently Asked Questions

What is LENZ Therapeutics Inc (LENZ) stock price today?

The current price of LENZ is 14.87 USD — it has decreased -2.43 % in the last trading day.

What is LENZ Therapeutics Inc (LENZ)'s business?

LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.

What is the price predicton of LENZ Stock?

What is LENZ Therapeutics Inc (LENZ)'s revenue for the last quarter?

LENZ Therapeutics Inc revenue for the last quarter amounts to 12.50M USD, decreased % YoY.

What is LENZ Therapeutics Inc (LENZ)'s earnings per share (EPS) for the last quarter?

LENZ Therapeutics Inc. EPS for the last quarter amounts to -0.59 USD, increased 55.26 % YoY.

What changes have occurred in the market's expectations for LENZ Therapeutics Inc (LENZ)'s fundamentals?

How many employees does LENZ Therapeutics Inc (LENZ). have?

LENZ Therapeutics Inc (LENZ) has 42 emplpoyees as of January 10 2026.

What is LENZ Therapeutics Inc (LENZ) market cap?

Today LENZ has the market capitalization of 465.28M USD.